Aclarubicin (HCl)

Aclarubicin (HCl) is antibiotic with antineoplastic or anticancerous properties, belonging to the anthracycline group. Aclarubicin isolated from Streptomyces galilaeus. Aclarubicin is less cardiotoxic than doxorubicin and daunorubicin. Aclarubicin (HCl) is effective in the treatment of different cancers (leukemias) to slow or stop the growth of cancerous cells or abnormal cells. Aclarubicin (HCl) is used in combination with different anticancerous drugs to obtain best therapeutic results and to reduce toxicity or side effects. Aclarubicin (HCl) is administered intravenously.

Aclarubicin (HCl) is primarily indicated in conditions like Acute non-lymphoblastic leukemia, Breast cancer, Gastric cancer, Lymphoma, Ovarian coma, Small cell lung cancer, Thyroid cancer.

Aclarubicin (HCl) is contraindicated in conditions like Neutropenia,Thrombocytopenia,Cardiac failure.

The severe or irreversible adverse effects of Aclarubicin (HCl), which give rise to further complications include Reversible ECG changes, Sinus tachycardia, Anemia, Hepatic insufficiency.Aclarubicin (HCl) produces potentially life-threatening effects which include Congestive heart failure. which are responsible for the discontinuation of Aclarubicin (HCl) therapy.The symptomatic adverse reactions produced by Aclarubicin (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Nausea, Vomiting, Alopecia, Anorexia.

Aclarubicin is not recommended for use during pregnancy or lactation. Immunosuppressent drug should not be given, where possible, to patients with acute infection, dosage reduction or withdrawal should be considered if infection develops, until the infection has been controlled. Blood counts and measurement of hemoglobin concentration should be carried out routinely; it helps to predict the onset of bone marrow depression. It must be handled with great care and avoid contact with skin and eyes and should not be inhaled.

Drug should not be given to Paediatrics, Pregnant Mothers, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

175 to 300 mg/sq.meter (240 (237.5)) 24 hourly IV — Initially for 3-7 Days 25 to 100 mg/sq.meter (62 (62.5)) As recommended. IV — Maintenance, Every 3-4 Weeks

No child dosage information is recorded for this medicine yet.

No neonatal dosage information is recorded for this medicine yet.

No data regarding the interactions of Aclarubicin (HCl) was found.

IV Inj Store at room temperature. Protect from Sunlight. IV Inj (reconstituted soln) Store Below 40°C. Use within 24 hrs if kept at room temperature.